Ryvu Therapeutics S.A. (WSE:RVU)
Poland · Delayed Price · Currency is PLN 16.80
+0.70 (4.35%)
Nov 4, 2026, 1:14 PM CET
Ryvu Therapeutics Stock Forecast
Stock Price Forecast
According to 5 analysts polled by S&P Global, Ryvu Therapeutics stock has a consensus rating of "Buy" and an average price target of zł 29.90. The average 1-year stock price forecast is 77.98% higher than the current stock price, while the lowest is zł 17.00 (+1.19%) and the highest is zł 46.00 (+173.81%).
Price Target: zł 29.90 (+77.98%)
Analyst Consensus: Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Ryvu Therapeutics stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | May '26 | Jun '26 | Jul '26 | Aug '26 | Sep '26 | Oct '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 2 | 2 | 1 | 2 | 2 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 2 | 3 | 3 | 3 | 3 | 3 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 5 | 5 | 4 | 5 | 5 |
Financial Forecast
Revenue This Year
158.60M
from 87.70M
Increased by 80.84%
Revenue Next Year
167.20M
from 158.60M
Increased by 5.42%
EPS This Year
-1.88
from -4.40
EPS Next Year
2.44
from -1.88
EPS and Forward PE are based on non-GAAP adjusted numbers. Financial currency is PLN.